This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Dr. Li et al. investigated the safety and efficacy of normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), compared with EVT alone, in 86 patients with acute ischemic stroke and large vessel occlusion in the anterior circulation in a single-center, proof-of-concept, assessor-blinded, randomized, controlled pilot study. NBO consisted of giving 100% oxygen through a face mask (10L/min for 4 hours) before vascular recanalization. The researchers found that the infarct volume at 24–48 hours was significantly smaller in the NBO group. In addition, the NBO group had a significantly lower median mRS at 90 days. The paper generated considerable interest from the readership, and several responses were received. In one response, Dr. Yin et al. propose that hyperbaric oxygen therapy (HBOT) could promote greater oxygen diffusion into ischemic tissues as a potential neuroprotective treatment. They suggest that HBOT, delivered in single or multiple sessions to mitigate adverse effects of prolonged exposure, would be a helpful comparator with NBO in future trials. Responding to this comment, the authors cite previous studies suggesting that a single round of HBOT delivered alone or after NBO may be more effective than NBO alone in treating transient ischemia in animal models. However, repeated daily HBOT had no additional benefit in those studies. They speculate that a single round of HBOT with EVT may be optimal. Nevertheless, they emphasize the ease of delivery of NBO compared with the need for a special pressuring device to deliver HBOT, which may result in treatment delays and may be more difficult to achieve while undergoing EVT.
Dr. Li et al. investigated the safety and efficacy of normobaric hyperoxia (NBO) combined with endovascular treatment (EVT), compared with EVT alone, in 86 patients with acute ischemic stroke and large vessel occlusion in the anterior circulation in a single-center, proof-of-concept, assessor-blinded, randomized, controlled pilot study. NBO consisted of giving 100% oxygen through a face mask (10L/min for 4 hours) before vascular recanalization. The researchers found that the infarct volume at 24–48 hours was significantly smaller in the NBO group. In addition, the NBO group had a significantly lower median mRS at 90 days. The paper generated considerable interest from the readership, and several responses were received. In one response, Dr. Yin et al. propose that hyperbaric oxygen therapy (HBOT) could promote greater oxygen diffusion into ischemic tissues as a potential neuroprotective treatment. They suggest that HBOT, delivered in single or multiple sessions to mitigate adverse effects of prolonged exposure, would be a helpful comparator with NBO in future trials. Responding to this comment, the authors cite previous studies suggesting that a single round of HBOT delivered alone or after NBO may be more effective than NBO alone in treating transient ischemia in animal models. However, repeated daily HBOT had no additional benefit in those studies. They speculate that a single round of HBOT with EVT may be optimal. Nevertheless, they emphasize the ease of delivery of NBO compared with the need for a special pressuring device to deliver HBOT, which may result in treatment delays and may be more difficult to achieve while undergoing EVT.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2022 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
